A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor

被引：0
作者：
Li, Saifeng [1 ,2 ]
Wen, Qin [1 ,2 ]
Huang, Wenwu [1 ,2 ]
Qiu, Zeyu [1 ]
Feng, Long [1 ]
Yi, Fengming [1 ]
机构：
[1] Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Minde Rd 1, Nanchang 330006, Peoples R China
[2] Nanchang Univ, Jiangxi Med Coll, Nanchang 330006, Peoples R China
来源：
WORLD JOURNAL OF SURGICAL ONCOLOGY | 2025年 / 23卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Hepatocellular carcinoma; Second line; Lenvatinib; PD-1; inhibitor; ARTERIAL INFUSION CHEMOTHERAPY; ATEZOLIZUMAB PLUS BEVACIZUMAB; SORAFENIB; SAFETY; REGORAFENIB; THERAPY;
D O I：
10.1186/s12957-025-03742-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PurposeThe incidence and mortality of hepatocellular carcinoma are still high according to National Cancer Center of China. Atezolizumab plus bevacizumab has become one of the standard regimens for the first-line treatment of unresectable hepatocellular carcinoma. However, some patients still use lenvatinib in combination with immunotherapy instead of a standard "atezolizumab-bevacizumab" regimen as a lower risk of bleeding in patients with esophagogastric varices. However, there is no evidence for second-line therapy after progression on lenvatinib combined with PD-1 inhibitor in unresectable hepatocellular carcinoma till now. Herein, we aim to investigate second-line treatment among these patients.Patients and methodsThirty-three patients with unresectable hepatocellular carcinoma with esophagogastric varices were admitted to the Second Affiliated Hospital of Nanchang University from January 2019 to December 2023. They were treated with lenvatinib in combination with PD-1 inhibitor as first line. The efficacy was conducted according to the RECIST1.1 criteria. The endpoints included objective response rate (ORR), disease control rate (DCR), median overall survival (OS), and median progression free survival (PFS).ResultsWe identified a total of 225 patients with unresectable hepatocellular carcinoma with esophagogastric varices who received first-line lenvatinib in combination with PD-1 inhibitor, of whom 33 (14.7%) received second-line therapy. 21 patients (63.6%) were treated with regorafenib combined with PD-1 inhibitor, 6 patients (18.2%) with apatinib plus PD-1 inhibitor, 4 patients (12.1%) with bevacizumab plus PD-1 inhibitor, and the remaining 2 patients with regorafenib or sorafenib as monotherapy, respectively. Of the 33 patients, 2 (6.1%) were evaluated as partial response (PR), 16 (48.5%) had stable disease (SD), and 15 (45.4%) experienced progression (PD). The ORR was 6.1%, and the DCR was 54.6%. Median PFS was 4.5 months, median OS was 7.2 months, and the 12-month OS rate was 27.3%. Overall survival follow-up was done in 37 patients without second line treatment whose baseline levels were matched with those of the treatment group. The OS was 7.2 months in second line treatment group versus 3.0 months in control group (p = 0.04). As for different treatments in a second line, The ORR of regorafenib in combination with PD-1 inhibitor was 9.5%, the DCR was 47.6%, the median PFS was 4.2 months, and the median OS was 5.9 months. None of the patients treated with apatinib plus PD-1 inhibitor got PR, the DCR was 83.3%, the median PFS was 8.7 months, and the median OS was 9.1 months. None of the patients treated with bevacizumab plus PD-1 inhibitor got PR, the DCR was 25.0%, the median PFS was 2.2 months, and the median OS was 6.0 months.ConclusionThe second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor is effective. Regorafenib or apatinib combined with PD-1 inhibitor might be the preferred options.
引用
收藏
页数：8
相关论文
共 40 条
  • [1] Sung H., Ferlay J., Siegel R.L., Et al., Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin May, 71, 3, pp. 209-249, (2021)
  • [2] Reig M., Forner A., Rimola J., Et al., BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update, J Hepatol Mar, 76, 3, pp. 681-693, (2022)
  • [3] Finn R.S., Qin S., Ikeda M., Et al., Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 14, 20, pp. 1894-1905, (2020)
  • [4] Finn R.S., Ikeda M., Zhu A.X., Et al., Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma, J Clin Oncol Sep, 10, 26, pp. 2960-2970, (2020)
  • [5] Llovet J.M., Kudo M., Merle P., Et al., Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial, Lancet Oncol Dec, 24, 12, pp. 1399-1410, (2023)
  • [6] Duan W.B., Wang X.H., Zhang G.C., He Z., Li S.Q., Zhou J., Efficacy of lenvatinib combined with PD-1 inhibitor versus Sorafenib and PD-1 inhibitor with or without TACE for hepatocellular carcinoma with extrahepatic metastasis, Immunotargets Ther, 13, pp. 247-258, (2024)
  • [7] Zhang B., Su L., Lin Y., Efficacy and safety of lenvatinib combined with PD–1/PD–L1 inhibitors in the treatment of hepatocellular carcinoma: A meta–analysis and systematic review, Oncol Lett Jul, 28, 1, (2024)
  • [8] Liu Q., Li R., Li L., Et al., Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience, Ther Adv Med Oncol, 15, (2023)
  • [9] Zhang W., Tong S., Hu B., Et al., Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial, J Immunother Cancer Sep, 11, 9, (2023)
  • [10] Zhang Y., Zhang H., Xu H., Wang Y., Feng L., Yi F., Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion, World J Surg Oncol May, 6, 1, (2024)
1234